ST. PAUL, Minn.--(CRWENewswire)--On a conference call with analysts and investors, 3M (NYSE:MMM) today will affirm its 2012 earnings-per-share target of $6.27 to $6.35 and provide a roadmap for the company’s 2013 performance expectations.

SAN DIEGO, Dec. 10, 2012 (CRWENewswire) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and development of innovative antibiotics for life-threatening infections, announced today that it has reached its enrollment objective of 658 patients in the last of its two Phase 3 clinical trials of tedizolid phosphate (TR-701) for the treatment of acute bacterial skin and skin structure infections (ABSSSI).